May 1, 2020

HER2-Positive Breast Cancer

The key of abemaciclib, fulvestrant, and trastuzumab revealed a significant rise in progression-free survival (PFS) versus standard-of-care chemotherapy plus trastuzumab while giving a tolerable safety…